Skip to main content
OXFORD BIODYNAMICS PLC logo

OXFORD BIODYNAMICS PLC — Investor Relations & Filings

Ticker · OBD ISIN · GB00BD5H8572 LEI · 2138005Y1TK258O5U928 IL Professional, scientific and technical activities
Open in API
Filings indexed 416 across all filing types
Latest filing 2017-11-15 Regulatory Filings
Country GB United Kingdom
Listing IL OBD

About OXFORD BIODYNAMICS PLC

https://www.oxfordbiodynamics.com/

Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests. The company's proprietary EpiSwitch® platform utilizes 3D genomics and epigenetic biomarkers to create diagnostic solutions for life-changing diseases, with a focus on oncology. Its portfolio of clinical tests includes the EpiSwitch® PSE, a blood test that assesses the likelihood of prostate cancer with high accuracy to help reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test designed to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. The platform enables the translation of 3D genome regulation into clinical applications for precision medicine at scale.

Recent filings

Filing Released Lang Actions
Data at FNIH Biomarker Consortium Cancer Meeting
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated 15 November 2017. The content describes a company (Oxford BioDynamics Plc) presenting data at a scientific symposium and includes commentary from the CEO. Crucially, the document ends with the explicit statement: "This information is provided by RNS The company news service from the London Stock Exchange END". This structure is characteristic of a general regulatory news service announcement, which serves as a broad disclosure mechanism. Since the content is an update on scientific progress and not a formal financial report (like 10-K or IR), a management change (MANG), or a specific shareholder vote result (DVA), the most appropriate classification is the general regulatory filing category, RNS.
2017-11-15 English
Agreement with a major US biopharma company
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and the date, followed by an announcement titled 'Oxford BioDynamics signs collaboration agreement with a major US biopharmaceutical company'. The content details a specific business event (a collaboration agreement) rather than periodic financial results (ER, IR, 10-K) or a general shareholder vote/meeting material (AGM-R, DEF 14A). Since this is a specific, material announcement released via the London Stock Exchange's news service (indicated by 'RNS Number' and 'The company news service from the London Stock Exchange'), it fits best under the general Regulatory Filings category (RNS), as it is not covered by the more specific codes like DIRS, MANG, or TAR. Given the document length is under 5,000 characters and it is a direct announcement, RNS is the most appropriate classification.
2017-11-07 English
Notification of major holdings
Major Shareholding Notification Classification · 98% confidence The document is clearly identified by the header 'RNS Number : 6695V' and the footer 'This information is provided by RNS The company news service from the London Stock Exchange'. The content is a 'TR-1: Standard form for notification of major holdings', which details changes in share ownership thresholds (crossing from 10.00% to 9.98%). This type of mandatory disclosure regarding insider or major shareholder transactions/holdings falls under the category of Director's Dealing (if it were a director) or, more generally, Major Shareholding Notification. Since 'Major Shareholding Notification' (MRQ) is an explicit category for changes in significant share ownership levels, this is the most appropriate classification. It is not a general regulatory filing (RNS) because a more specific category exists.
2017-11-06 English
Presents at the Diabetes Asia 2017 Conference
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated October 13, 2017. The content describes a company (Oxford BioDynamics Plc) presenting a poster at a conference and detailing the findings related to their EpiSwitch™ technology for stratifying diabetes patients. This is a specific corporate announcement regarding scientific/business development, not a full financial report (10-K, IR), a management change (MANG), or a dividend notice (DIV). Since it is a formal announcement disseminated via the London Stock Exchange's news service (indicated by 'RNS Number' and 'The company news service from the London Stock Exchange'), and it doesn't fit neatly into the other specific categories like ER, CT, or IP, the most appropriate general regulatory announcement category is RNS (Regulatory Filings). It is not an announcement *about* a report (RPA), but the report/update itself.
2017-10-13 English
Presents ALS signatures at NEALS
Regulatory Filings Classification · 95% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement from the London Stock Exchange's news service (RNS). The content describes a presentation given by a company director at a scientific consortium meeting (NEALS) regarding new diagnostic and prognostic biomarkers for ALS. This is not a full annual report (10-K), an earnings release (ER), or a formal investor presentation (IP). It is a specific update about scientific progress and participation in an industry event. Since it is a general regulatory announcement that doesn't fit the highly specific categories like DIRS, DIV, or CAP, the most appropriate fallback category is Regulatory Filings (RNS). The document length (5328 chars) is substantial enough that it is the announcement itself, not just a notice to download a larger report.
2017-10-11 English
Announces grant of US patent for EpiSwitchT
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and the date '03 October 2017', indicating it is a regulatory announcement disseminated via the London Stock Exchange's RNS service. The content announces the grant of a US patent for the company's proprietary technology platform, EpiSwitch™. This is a specific corporate event announcement related to intellectual property and market positioning, not a full financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). Since the announcement is a formal regulatory disclosure that doesn't fit neatly into the other specific categories (like CAP, LTR, or DIRS), the most appropriate classification is the general regulatory filing category, RNS, which serves as a fallback for miscellaneous regulatory announcements.
2017-10-03 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.